Surgery vs radiotherapy in the management of biopsy Gleason score 9-10 prostate cancer and the risk of mortality
Importance It is unknown how treatment with radical prostatectomy (RP) and adjuvant
external beam radiotherapy (EBRT), androgen deprivation therapy (ADT), or both …
external beam radiotherapy (EBRT), androgen deprivation therapy (ADT), or both …
[HTML][HTML] Predicting prostate cancer specific-mortality with artificial intelligence-based Gleason grading
Background Gleason grading of prostate cancer is an important prognostic factor, but suffers
from poor reproducibility, particularly among non-subspecialist pathologists. Although …
from poor reproducibility, particularly among non-subspecialist pathologists. Although …
Declining use of radiotherapy for adverse features after radical prostatectomy: results from the National Cancer Data Base
HM Sineshaw, PJ Gray, JA Efstathiou, A Jemal - European urology, 2015 - Elsevier
Background Patterns of postoperative radiotherapy (RT) use in prostate cancer (PCa) after
the publication of major randomized trials have not been well characterized. Objective To …
the publication of major randomized trials have not been well characterized. Objective To …
[HTML][HTML] Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only
HC Rischke, W Schultze-Seemann, G Wieser… - Strahlentherapie und …, 2015 - infona.pl
Background Nodal pelvic/retroperitoneal recurrent prostate cancer (PCa) after primary
therapy can be treated with salvage lymph node dissection (salvage-LND) in order to delay …
therapy can be treated with salvage lymph node dissection (salvage-LND) in order to delay …
[HTML][HTML] Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy
MJ Roberts, A Morton, N Papa, A Franklin… - European Journal of …, 2022 - Springer
Purpose The prognostic value of PSMA intensity on PSMA PET/CT due to underlying
biology and subsequent clinical implications is an emerging topic of interest. We sought to …
biology and subsequent clinical implications is an emerging topic of interest. We sought to …
Genomic classifier augments the role of pathological features in identifying optimal candidates for adjuvant radiation therapy in patients with prostate cancer …
D Dalela, M Santiago-Jiménez, K Yousefi… - Journal of Clinical …, 2017 - ascopubs.org
Purpose Despite documented oncologic benefit, use of postoperative adjuvant radiotherapy
(aRT) in patients with prostate cancer is still limited in the United States. We aimed to …
(aRT) in patients with prostate cancer is still limited in the United States. We aimed to …
Noninferiority of hypofractionated vs conventional postprostatectomy radiotherapy for genitourinary and gastrointestinal symptoms: the NRG-GU003 phase 3 …
MK Buyyounouski, SL Pugh, RC Chen, MJ Mann… - JAMA …, 2024 - jamanetwork.com
Importance No prior trial has compared hypofractionated postprostatectomy radiotherapy
(HYPORT) to conventionally fractionated postprostatectomy (COPORT) in patients primarily …
(HYPORT) to conventionally fractionated postprostatectomy (COPORT) in patients primarily …
Very early salvage radiotherapy improves distant metastasis-free survival
Purpose: Early salvage radiotherapy following radical prostatectomy for prostate cancer is
commonly advocated in place of adjuvant radiotherapy. We aimed to determine the optimal …
commonly advocated in place of adjuvant radiotherapy. We aimed to determine the optimal …
Propensity-weighted long-term risk of urinary adverse events after prostate cancer surgery, radiation, or both
Background Prostate cancer is the second most common cancer in men and has high
survivorship, yet little is known about the long-term risk of urinary adverse events (UAEs) …
survivorship, yet little is known about the long-term risk of urinary adverse events (UAEs) …
RETRACTED: Recommandations françaises du Comité de Cancérologie de l'AFU–Actualisation 2018–2020: cancer de la prostate
F Rozet, C Hennequin, JB Beauval, P Beuzeboc… - Progrès en urologie, 2018 - Elsevier
Author links open overlay panel F. Rozet ab, C. Hennequin ac, J.-B. Beauval ad, P.
Beuzeboc ae, L. Cormier af, G. Fromont-Hankard ag, P. Mongiat-Artus ah, G. Ploussard ai …
Beuzeboc ae, L. Cormier af, G. Fromont-Hankard ag, P. Mongiat-Artus ah, G. Ploussard ai …